CASC16 and breast carcinoma: The former overlaps with the gene FGFR2, the latter with CASC16 and the protein-coding gene TOX3. Variants in both FGFR2 and TOX3 have been repeatedly associated with breast cancer susceptibility in other case-control studies [42], in studies on BRCA1 and BRCA2 carriers [44], and in hereditary breast and ovarian cancer families negative for mutations in BRCA1 and BRCA2 [45].